Edesa Biotech, Inc. (EDSA) News
Filter EDSA News Items
EDSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EDSA News Highlights
- For EDSA, its 30 day story count is now at 2.
- Over the past 25 days, the trend for EDSA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EDSA News From Around the Web
Below are the latest news stories about EDESA BIOTECH INC that investors may wish to consider to help them evaluate EDSA as an investment opportunity.
Edesa Biotech Reports Fiscal Year 2023 ResultsTORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning! |
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study1.0% Formulation Reached Primary Endpoint with Statistical SignificanceFull Analysis Identified Additional Efficacy SignalsTORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company ... |
Edesa Biotech to Present at Dermatology Drug Development SummitTORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled ... |
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS DrugTORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal ... |
EDSA: Secures up to CAD$23 Million to Fund Development of EB05…By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Up to CAD$23 Million to Fund Development of EB05 On October 12, 2023, Edesa Biotech, Inc. (NASDAQ:EDSA) announced it has secured a commitment of up to CAD$23 million from the Government of Canada to help cover expenses for the Phase 3 portion of the Phase 2/3 clinical trial for EB05, the company’s lead development |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! |
Edesa Biotech Secures $10 Million Credit Facility with Company FounderRevolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory ... |
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal GovernmentTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of ... |